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Abstract: Sphingolipidoses are inherited genetic diseases characterized by the accumulation of
glycosphingolipids. Sphingolipidoses (SP), which usually involve the loss of sphingolipid hydrolase
function, are of lysosomal origin, and represent an important group of rare diseases among lysosomal
storage disorders. Initial treatments consisted of enzyme replacement therapy, but, in recent decades,
various therapeutic approaches have been developed. However, these commonly used treatments
for SP fail to be fully effective and do not penetrate the blood–brain barrier. New approaches,
such as genome editing, have great potential for both the treatment and study of sphingolipidoses.
Here, we review the most recent advances in the treatment and modelling of SP through the
application of CRISPR-Cas9 genome editing. CRISPR-Cas9 is currently the most widely used method
for genome editing. This technique is versatile; it can be used for altering the regulation of genes
involved in sphingolipid degradation and synthesis pathways, interrogating gene function, generating
knock out models, or knocking in mutations. CRISPR-Cas9 genome editing is being used as an
approach to disease treatment, but more frequently it is utilized to create models of disease. New
CRISPR-Cas9-based tools of gene editing with diminished off-targeting effects are evolving and
seem to be more promising for the correction of individual mutations. Emerging Prime results and
CRISPR-Cas9 difficulties are also discussed.
Keywords: sphingolipidoses; lysosomal storage diseases; CRISPR-Cas9; Gaucher disease;
Fabry disease; Tay–Sachs disease; Sandhoff disease; Niemann–Pick disease; Krabbe disease;
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1. Lysosomal Storage Diseases and Sphingolipidoses
The present study was based on high-quality, peer-reviewed publications available at NCBI
Pubmed until October 2019. The following work aims to provide a review covering the application of
CRISPR-Cas9, with a focus on sphingolipidoses.
Lysosomal storage diseases (LSDs) are an important subdivision of inherited metabolic diseases.
As a group, these monogenic diseases are estimated to affect 1 in 7500 newborns [1].
Generally, LSDs are multisystemic and degenerative. Patients present a continuum of disease
severity, which are usually classified by the type of disorder and the age of onset of clinical signs.
Different types of defects may underlie LSDs, including, but not limited to, defects in lysosomal
hydrolases, lysosomal membrane proteins, activator proteins, or transport proteins. Nevertheless,
they all present a common feature, which is the storage of macromolecules in the lysosomes. When
one of the several lysosomal hydrolases is dysfunctional, or has lost activity, due to mutations or
incorrect protein folding, the related substrate accumulates inside the cell. Depending on the type
of storage materials, LSDs are classically divided in subgroups that reflect the analogous affected
lysosomal pathway. Such is the case, for example, of the sphingolipidoses, mucopolysaccharidoses,
Int. J. Mol. Sci. 2019, 20, 5897; doi:10.3390/ijms20235897 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 5897 2 of 16
and glycoproteinoses. Additionally, there are diseases involving integral membrane proteins, disorders
of lysosome-related organelles, and disorders involving lipofuscin [2].
Sphingolipidoses are a subgroup of LSDs usually caused by defective sphingolipid hydrolases
that act upon the sphingolipid degradative pathway. Most sphingolipidoses present autosomal
recessive inheritance. In some population groups, a few mutations account for a large proportion
of the mutant variants. Nevertheless, a myriad of mutations can cause these disorders. Mutated
genes coding for sphingolipid hydrolases or deregulation of lysosomal-related proteins are at the basis
of sphingolipidoses. In these diseases, cells are unable to degrade specific lipids (Figure 1), which
then accumulate inside the cell until reaching toxic or nonfunctional levels, leading to multisystemic
pathologies [3–5].
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For instance, causal mutations of Gaucher disease are considered to constitute a risk for Parkinson’s 
disease. Therefore, diseases involving mutant glycosphingolipids represent a significant 
multidimensional problem. Moreover, recent results in Niemann–Pick A/B demonstrate a tight link 
between cellular sphingolipid metabolism and immunity, which supports the hypothesis of a central 
Figure 1. GM1-gangliosidosis degradation pathway, sphingolipid synthesis pathway, and enzyme
activity recovery with CRISPR-Cas9 and DNA template. The red lines describe the interrupted pathway
of degradation due to a specific dysfunctional enzyme. In bold are the names of the sphingolipidoses
caused by the mutated enzymes and the consequent interrupted pathways. Scheme drawn on the basis
of the bibliography used in this review.
These rare disorders have been associated with other frequent diseases, most likely because the
toxic effects on the cells makes them prone to th developm nt of other, more com n dis ases [6,7]. For
instance, causal mutations of Gaucher disease are considered to constitute a risk for Parkinson’s disease.
Therefore, dise ses involving mutant glycosphingolipids represent a significant multidimensional
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problem. Moreover, recent results in Niemann–Pick A/B demonstrate a tight link between cellular
sphingolipid metabolism and immunity, which supports the hypothesis of a central role of sphingolipids
in processes beyond those of the lysosome [8]. Recently, a transcription factor EB (TFEB), which
is responsible for the transcription coordination of most lysosomal genes, has been identified, this
transcription controller provides a new tool to manipulate and study lysosomal diseases [9]. The
discovery of TFEB led to the search for a motif associated with genes with lysosomal function, and the
coordinated expression resulted in the identification of a new mechanism, the coordinated lysosomal
expression and regulation (CLEAR) [10].
Although the LSDs are rare, research in the field has been abundant; LSDs have been the stage for
the development of new therapies and have provided knowledge that extends beyond LSDs.
1.1. Gaucher Disease
The most common sphingolipidosis is Gaucher disease (GD). It is caused by mutations in the
GBA1 gene that encodes lysosomal acid-β-glucocerebrosidase (GCase), the enzyme responsible for
the degradation of glucosylceramide (GlcCer). The Gaucher′s macrophage is the classic pathologic
hallmark of the disease, presenting a lysosomal compartment enlarged by the storage of undegraded
glycolipid molecules. These cells have a pivotal role in the development of the disease since they are
capable of inducing local tissue reactions [1].
Depending on the level severity, deterioration, and type of impairment, GD can be categorized
in three main groups, type I, II, and III. The most frequent form of GD is type I, also known as
nonneuropathic GD as it spares the nervous system. Thus, it is considered to be the less aggressive
form of GD. It can be subdivided according to the age of onset and may have clinical onset at any
time during the human life cycle [6,11]. Types II and III are characterized by the presence of primary
neurologic disease affecting the central nervous system (CNS). Type II is the most severe form of GD—it
has severe and rapid degeneration leading to death before 2–4 years of age [12,13]. Type III usually
has a later onset with slower progression. In spite of the three conventional GD classifications, GD
presents an important continuum of clinical forms. The symptoms of Gaucher are extensive, affecting
many organs systems, such as skeletal, cardiovascular, and neurological. In some cases, GD variants
have been associated with other neurological diseases such as Parkinson’s disease and peripheral
neuropathy [6,11].
GD can be caused by GBA1 mutations or, less frequently, by mutations in the gene coding for the
activator protein saposin C. The application of new sequencing approaches leads to a continuously
growing number of GBA1 mutations. Nevertheless some mutations have been reported as more
frequent in specific population groups [12–14].
The degree of endoplasmic reticulum retention (ER) and proteasomal degradation has recently
been proposed as an important factor influencing the outcome of GCase mutants. Different mutations
in GBA1, which impact the ability of the protein to fold correctly, present variable levels of ER retention
and undergo ER-associated degradation (ERAD) in the proteasome [15].
It is known that GD patients are at a higher risk to develop Parkinson′s disease (PD) in comparison
to the non-GD population. Thus, the mutated GCase seems to be a predisposing factor for the
development of PD. Mutant GCase contributes to the accumulation and aggregation of α-synuclein,
one of the main causes of PD, which may be a reason for pathological interaction [16]. The presence of
mutant GCase is also thought to lead to the enhancement of neuronal vulnerability to neurodegenerative
processes, triggered by increased alpha-synuclein expression [17] and by ERAD, which is also known
to be involved in the process leading to Parkinson′s disease [15].
1.2. Fabry Disease
Fabry disease (FD) is a sphingolipidosis caused by a mutated alpha-galactosidase A, encoded
by the GLA gene. FD follows an X-inheritance pattern, but methylation skewing can also lead to
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female presentation of the disease. When the enzyme is nonfunctional or not present, its substrate,
globotriaosylceramide (Gb3), accumulates in the lysosomes [18,19].
The classic form of FD is clinically heterogeneous, with different symptoms along the patient’s life,
and usually has more severe clinical expression in males than in females. The lifespan is decreased,
often due to renal failure, heart diseases, and strokes. However, there are also reports of late-onset
Fabry disease in males, involving only a single organ system (cardiac or renal) due to missense
mutations that lead to sufficient residual enzyme activity that prevent symptoms in childhood and
early adulthood [20,21].
1.3. GM2-Gangliosidoses
Tay–Sachs Disease (TSD) is one of the most common GM2-gangliosidoses, the substrate is the
main glycolipid of neuronal cell plasma membranes. GM2-gangliosidoses are a group of autosomal
recessive LSDs related to deficiency in lysosomal hexosaminidases (Hex). Deficient enzyme activity
leads to abnormal accumulation of GM2 ganglioside and impaired neuronal cellular activity [22].
Defects in the gene-coding ganglioside GM2 activator protein (GM2A) also lead to TSD. The Hex
enzymes are all dimers encoded by the same two genes, HEXA (encodes α subunit) and HEXB (encodes
β subunit). HexA enzyme is composed of subunits α and β, and HexB by two β subunits [23]. In the
case of TSD, HexA enzyme is mutated whereas in Sandhoff disease (SD), it is HexB that is mutated.
SD is classified in three main age-related forms: (1) infantile, with progressive neurologic
impairment, hypotonia, bilateral cherry-red spots in the retina, and seizures; (2) juvenile, with
dementia, cerebellar ataxia, mental retardation, and spinal muscular atrophy; and (3) adult, with
spinocerebellar degeneration or motor neuron disorders [24].
TSD is also classified by age of onset. The infantile form is characterized by mental and motor
developmental delay, hypotension, cherry-red spots, and dysphagia; the juvenile form is characterized
by ataxia and spasm progression; and the later-onset form is characterized by gradual decline in motor,
cerebral, and spinocerebellar function [25].
Variant B1, particularly prevalent in populations of Northern Iberian descent, particularly in
individuals of Portuguese ancestry, is due to a higher frequency of a specific HEXA mutation. This
atypical juvenile variant is characterized by differential activity towards sulphated and nonsulphated
substrates. The deficiency in this enzyme has altered kinetic properties due to active site disturbance.
In most cases, this variant is caused by at least one c.533 G > A allele [26,27].
1.4. Niemann–Pick Disease
Niemann–Pick diseases (NPD) are autosomal recessive inherited diseases subdivided into
hydrolase deficient entities or trafficking-impaired disorders. In acid sphingomyelinase-deficient
NPD (ASM-deficient NPD), underlying defects are due to SMPD1 gene mutations (type A, B, and
intermediate forms), whereas in NP type C (NPC), which is currently described as a cholesterol
trafficking defect, is due to NPC1 or NPC2 gene mutations [28,29]. NPC was historically classified as a
sphingolipidosis, but it is not caused by a deficiency in sphingolipid catabolism. Rather, it is caused by
a cholesterol trafficking defect.
The ASM is a lysosomal enzyme which degrades sphingomyelin. When the enzyme is not
present or is nonfunctional, sphingomyelin accumulates in different organs. Type A NPD leads to
hepatosplenomegaly and severe CNS problems in infancy, with a frequent lifespan of only 2–3 years
after birth. Type B NPD causes hepatosplenomegaly and lung problems, but typically does not impact
the CNS. Frequently, NPD diseases cause lipid storage and foam cell infiltration in tissues, pulmonary
insufficiency, and central nervous system issues [30,31].
1.5. Krabbe Disease
Like most LSDs, Krabbe Disease (KD) is an autosomal recessive disease. Its underlying causal
deficiency is in the lysosomal enzymeβ-galactocerebrosidase (Galc), which results from a mutated GALC
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gene that encodes that enzyme. When deficiency of such enzyme is present, galactosylceramide, the
major natural substrate, accumulates in lysosomes. This sphingolipid contains sphingosine, galactose,
and fatty acid, and is almost exclusively localized in the myelin sheath [32]. Besides galactosylceramide,
Galc has other substrates: galactosylsphingosine or psychosine, monogalactosyldiglyceride, and the
precursor of seminolipid. Additionally, KD can also be associated with the mutated activator protein,
saposin A [32].
This disease damages the white matter of the brain; it is also known as globoid cell leukodystrophy.
KD has been subdivided into four age/symptom-based types. The most common subtype, which
presents faster progression, is early infantile type (birth–5 months) the symptoms include irritability,
regression of psychomotor development, feeding difficulties, and, as the disease progresses,
hypertonicity, seizures, loss of vision and hearing, and early death. At the other end of the spectrum
is the adult type (>16 years) with slow development of progressive spastic paraparesis or gait
abnormalities [33,34].
1.6. GM1-Gangliosidosis and Morquio B Syndrome
The deficient activity of the lysosomal hydrolase β-galactosidase (β-gal), coded by GLB1,
can result in two distinguishable clinical entities, GM1-gangliosidosis and Morquio B syndrome.
GM1-gangliosidosis is caused by lysosomal accumulation of ganglioside GM1 and its derivative GA1.
GM1-gangliosidosis is a neurodegenerative disease with GM1-ganglioside accumulation impairing
neuronal functioning, whereas Morquio B is a progressive condition that mainly affects the skeleton
and has an accumulation of keratan sulfate, which is excreted in the urine.
GM1-gangliosidosis is characterized by progressive neurologic dysfunction, presenting different
degrees of severity depending on the subtype, which is subdivided according to the age of onset into
Type I (infantile), Type II (late infantile/juvenile), and Type III (adult) [35].
Allelic mutations of the GLB1 gene cause heterogeneous clinical phenotypes, such as
GM1-gangliosidosis and Morquio B syndrome. An important structural model of the protein was
created and is convenient for modelling the mutant variants in order to better understand the structural
bases of the diseases [36]. The existence of intermediate phenotypes that are clinically difficult to
distinguish demonstrates the need to further investigate the disease. The in silico analysis and
three-dimensional modelling of mutated GLB1 proteins are most helpful, but still not sufficient to fully
differentiate between the two entities or establish a genotype/phenotype correlation [37].
1.7. Current Treatments for Sphingolipidoses
Currently, the most common treatments for sphingolipidoses are enzyme replacement therapy
(ERT), substrate reduction therapy (SRT), and pharmacological chaperones (PC). ERT is currently
the most widely used treatment. However, ERT has a variety of limitations. One major difficulty is
that the replacement enzymes are not capable of crossing the blood–brain barrier. Additionally, all
of the aforementioned therapeutic approaches are transitory and require periodically administration
of the therapeutic agent. Furthermore, in the case of ERT, there is potential for an immunological
reaction to the replacement enzyme. SRT is capable of targeting more than one sphingolipidosis as
it utilizes inhibitors to block glycosphingolipid synthesis. However, this method can lead to partial
depletion of glycosphingolipids from the plasma membrane, which can result in severe side effects due
to off-targeting of the inhibitors (even targeting nonlysosomal enzymes) or other unknown interactions.
Unlike most ERTs, some of the molecules used for SRT are able to cross the blood–brain barrier. PC
treatment can only be successfully used in variants of diseases that are caused by enzyme misfolding,
as chaperones assist in protein folding processes. As in the case of STR, this method is also prone to
off-targeting [4,5].
ERT was the first therapy applied to sphingolipidoses and it resulted from a series of observations
from various scientists; in terms of therapeutic advances, it was most important and provided the
Int. J. Mol. Sci. 2019, 20, 5897 6 of 16
stepping stone for many other ERTs that are now available [38]. Concomitantly, it also brought upon
these rare diseases a great interest from social, scientific, medical, and pharmaceutical points-of-view.
2. CRISPR-Cas9 and Prime Editing Background
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats) is a programmable tool
for site-specific gene editing with low cost, easy application, and high efficiency when compared to
other well-known gene editing tools like TALEN (transcription activator-like effector nuclease) and
ZFN (zinc finger nuclease [39].
Type II CRISPR-Cas9 complex, as the name suggest, is composed of the Cas9 nuclease and a
guide RNA (gRNA). When bound to DNA correctly, the Cas9 catalyzes a double-strand break (DSB)
at the target site. Depending of the organism of origin, the Cas9 endonuclease can be structurally
and functionally different. The most widely used and tested Cas9 is the Streptococcus pyogenes Cas9
(SpCas9), which requires a PAM (protospacer-adjacent motif) sequence downstream and adjacent
of the target site to properly bind to the DNA sequence, which will then cut. For SpCas9 the PAM
sequence is NGG, where N is any DNA nucleotide and G is guanine. This sequence occurs at a high
frequency in the genome, allowing CRISPR-Cas9 to target virtually any gene. HNH and RuvC are
the nuclease domains of Cas9 that allow for the DSB of the DNA [40]. When one of the domains is
mutated, preventing the Cas9 from making DSB, a nickaseCas9 (nCas9) is produced. nCas9 is used to
nick DNA, or to decrease off-targeting using two gRNAs complexed with nCas9 for DSB [41].
If both domains are inactive, the Cas9 complex acts as an inhibitor, preventing transcription of a
certain gene by binding to the DNA area that constitutes that gene, but without cutting. This type of
Cas9 tool is commonly known as dead Cas9 (dCas9) [42].
In addition to Cas9, a guide RNA is also necessary for targeting the DNA sequence. Together,
CRISPR RNA (crRNA) and transactivating crRNA (tracrRNA) form the gRNA (two RNA chains
bounded). This can also be fully synthesized in one piece, known as a synthetic single-guide RNA
(sgRNA), composed of one RNA chain. gRNA binds to the Cas9 in order to form the ribonucleoproteic
complex known as CRISPR-Cas9. The gRNA is complementary to the complementary chain of the
target sequence and the crRNA part is composed of 20 nucleotides that bind to the DNA (Figure 2).
The conserved 3′-end scaffold of gRNA (tracrRNA) binds to Cas9 due to the presence of a stem-loop
structure in is end [40].
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Even though there is the need for a PAM adjacent to the target site, the sequence (5′-NGG-3′)
highly occurs in the genomes, thus, CRISPR-Cas9 can target virtually any gene. Even though this
tool has many advantages, it also has its cons, a major one is the possibility of off-targeting due to
homology with other sites [40].
The cleavage of the DNA creates a double-strand break (DSB) that is naturally repaired by the
cell using one of two mechanisms. Usually it is repaired by the nonhomologous end joining (NHEJ)
pathway, which introduces a small insertion or deletion (InDel) at the DSB site. However, the InDel
normally disrupts the gene, which could subsequently impact structure and function of the resulting
protein. The other pathway of repair, called homology-directed repair (HDR), uses, if existent (sister
chromatid [43]) or added, a donor DNA fragment with homology to the flanking sequence that is
integrated into the genome at the DSB site, thus repairing the broken DNA [44].
One of the limitations of using CRISPR-Cas9 technology for permanent gene modification is the
efficiency of integration of the complex and donor template in living cells and the possible loss of cell
viability due to the transfection process.
CRISPR-Cas9 integration can be carried out with plasmids or transcripts capable of expressing
Cas9 and gRNA genes, or by directly transfecting the ribonucleoprotein (RNP) complex previously
assembled in vitro [45].
The transformation can be achieved with electroporation, lipofection, polymeric nanoparticles,
cell-penetrating peptides, or virus-like retroviruses and lentiviruses. However, disruption of the cell
membrane is an aggressive procedure that results in many cell casualties. Furthermore, liposomes and
viruses are limited by efficiency and size, and in vitro complexes can be toxic to the cells due to their
exogenous nature [45].
Depending on the model and objective, the genome editing approach can change, but the highest
nuclease activity is achieved with RNP. The RNP approach is reliable not only in cells, but also in
embryos and in vitro assays. This approach is the most convenient and functional, since the complex
synthesis is not dependent on DNA or mRNA expression by the cells to be edited. Moreover, it is the
best method to avoid off-targeting due to the shorter exposure to the genome [46].
When a mutation in a specific gene leads to a nonfunctional protein, gene editing has the
potential to repair this issue. In cases where a few mutations represent a large proportion of the
causal alleles, it is possible to correct each mutation independently. Examples of such an approach
exist in other pathologies, such as Duchenne muscular dystrophy [47], cystic fibrosis [48], chronic
myeloid leukaemia [49], dominant progressive hearing loss [50], and autosomal dominant retinitis
pigmentosa [51]. In brief, with CRISPR-Cas9, DSB can be performed in the mutated gene to correct the
nonfunctional gene and potentially re-establish enzyme synthesis, and with an added donor DNA
template (with a correct gene sequence), it is also possible to use DSB to insert a functional gene for
synthesis of a functional enzyme.
Recently, a new revolutionary CRISPR-Cas9-based editing tool has been developed. This
technology is known as Prime editing and can mediate targeted insertions, deletions, all 12 possible
base-to-base conversions, and combinations in human cells without requiring DSBs or donor
DNA templates.
This tool is composed of a nickase Cas9 fused with a reverse transcriptase (RT) that targets DNA
using a guide RNA containing a spacer sequence that hybridizes with the target DNA. However,
the sgRNA is engineered to have specificity to the DNA target and the new genetic information that
replaces target DNA nucleotides. The DNA is nicked at the target site to expose a 3′-hydroxyl group
that primes the reverse transcription of an edit-encoding extension on the engineered guide RNA
(prime editing guide RNA—pegRNA) directly into the target site. This creates a heteroduplex with an
edited and a nonedited strand. Subsequently, the cell’s natural repair mechanisms kicks in. To increase
the chances of the DNA reparation mechanisms using the edited strand as template for reparation, a
nick is created in the nonedited DNA. The nick is made with a normal sgRNA and nickase Cas9. This
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circumvents the heteroduplex issue by preferentially replacing the nonedited strand in the reparation
process with a copy of the edited strand.
Prime editors1 (PE) use a RT fused to a RNA-programmable nickase and a pegRNA. PE2 uses
an engineered RT to increase editing efficiencies, and PE3 nicks the nonedited strand to induce
its replacement and further increase editing efficiency, typically to 20%–50% with 1%–10% indel
formation (percentages of human embryonic kidney (HEK) 293T cell testing). PE3b is a PE3 system
that additionally uses sgRNAs with spacers that match the edited strand, but not the original allele.
This allows for a nick in the nonedited strand only after editing, minimizing concurrent nicks, DSB,
and indel formation. Mismatches between the spacer and the unedited allele disfavor sgRNA nicking
until editing of the PAM strand is completed. This system results in 13-fold lower average indels
(0.74%) compared to PE3, without a decrease in edition efficiency [52].
3. CRISPR-Cas9 Edition for Disease Models and Therapeutic Approaches of Sphingolipidoses
Gene editing with CRISPR-Cas9 has been carried out to generate models of sphingolipidoses, and
in a few such diseases, as an attempt at therapy (Table 1). In diseases where a partial reestablishment
of function is enough to prevent the deleterious effect (such as many LSDs), CRISPR-Cas9 could be
more widely used.
With CRISPR-Cas9, DSB can be performed in the mutated gene to correct the nonfunctional gene
and potentially re-establish enzyme synthesis. With an added donor DNA template with a correct gene
sequence, it is also possible to use DSB in order to insert a functional gene for synthesis of a functional
enzyme. The use of Prime editing is also an option for the correction of specific nucleotide mutations,
without the need of a DNA donor template or DSB.
3.1. Gaucher Disease
CRISPR-Cas9 has not been used yet for gene therapy in GD, but models have been generated
(Table 1). Specifically, HEK 293T cells and A549 (adenocarcinomic human alveolar basal epithelial)
cells have been used for disease modelling by knocking out the GBA1 gene, using CRISPR-Cas9. The
study aimed at observing the importance of the GCase enzyme in endocytic trafficking of viruses and
exocytic transport. The results suggest diminished infection in both knockout cell lines when infected
with influenza virus [53].
In addition to cellular models, in vivo models have been created. Recently, two zebrafish models
that exhibit glucocerebrosidase deficiency have been generated using CRISPR-Cas9. Knockout of the
genes GBA1 and GBA2 has been carried out in wild-type zebrafish AB/TL strain embryos. Once reaching
adulthood, the knockout models were outcrossed to ABTL WT zebrafish. GBA1 zebrafish mutants
were heterozygous and GBA2 mutants were homozygous. Double mutant larvae were then generated
by crossing both GBA1 and GBA2 mutants. These models were used to study glucosylsphingosine and
glucosylated cholesterol level variations in the presence of glucocerebrosidase deficiency [54].
3.2. Fabry Disease
Several researchers have applied CRISPR-Cas9 to FD. In 2016, researchers used CRISPR-Cas9 for
gene knockout of GLA (in exon 1) in HEK 293T cells to create in vitro drug screening models for FD.
More specifically, they aimed to design a FD model to study enzyme replacement therapy (ERT) with
recombinant human α-Gal-A (rhα-GLA) [55].
A similar study also employed CRISPR-Cas9 to create a FD cell model to evaluate the amenability
to chaperone therapy. In this case, the target was exon 3 of the GLA gene in HEK 293T cells. Although the
target site was specific, single-cell analysis revealed different GLA mutations triggered by CRISPR-Cas9,
partially leading to a complete loss of enzymatic function. Therefore, this model was successful in
acquiring a disrupted GLA gene, but the method was not very encouraging since multiple mutations
were found for a supposedly specific cutting tool [56].
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Table 1. Sphingolipidoses and CRISPR-Cas9 use in disease models and gene/cell therapy.
Genes Enzymes Substrates Disease
CRISPR-Cas9 for Disease Models: CRISPR-Cas9 Gene/Cell
Therapy ReferencesCell Models In vivo Models
GBA1 Glucocerebrosidase Glucosylceramide Gaucher disease - HEK cells- A549 cells - Zebrafish X [53,54]
GLA α-galactosidase A Globotriaosylceramide Fabry disease
- HEK cells
- hESCs
- Podocytes
- Human
endothelialcells
- Rat
- Mouse
- Restoration of GLA
enzyme activity in FD
patient′s Fibroblasts with
mutation knockout
[55–61]
HEXA α-hexosaminidases-hexosaminidase GM2-ganglioside Tay-Sachs disease - HEK cells X
- Gene correction of
HEXA 1278+TATC
mutation in HEK293T cell
using Prime editing
[62]
HEXB α-hexosaminidase
β-hexosaminidase GM2-ganglioside Sandhoff disease - iPSCs X
- No accumulation of
GM2 ganglioside in iPSCs
generated from fibroblasts
of infantile SD patients
due to template knockin
[52,63]
SMPD Acidsphingomyelinase Sphingomyelin
Niemann-pick
diseases - HeLa cells - Zebrafish X [64–66]
GALC β-galactocerebrosidase Galactolipids Krabbe disease X - Zebrafish
- Cell therapy with
CRISPR-Cas9 edited
hNSCs with correct
enzyme activity
[67,68]
GLB1 β-galactosidase GM1-ganglioside GM1-gangliosidosis - iPSCs - Mouse X [69,70]
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In addition to HEK 293T cells, human embryonic stem cells (hESCs) have also been used to
create FD models. A GLA knockout was generated for further differentiation into cardiomyocytes
and proteome study. The model was made in order to study autophagic dysfunction and exosome
secretion in FD-associated hypertrophic cardiomyopathy [57].
Other cases of FD models have been generated with other cell lines, namely human immortalized
podocyte model of FD [58] and a human endothelial cell line, both with GLA disruption using
CRISPR-Cas9 tools [59].
CRISPR-Cas9 technology has also been used to generate in vivo models including the
GLA-knockout rat. The rat model is completely deficient in α-Gal-A activity; accumulates the
established GSL biomarkers, Gb3 and lyso-Gb3; and develops mechanical pain behavior. This model
was used to study the cation channel transient receptor potential ankyrin 1 (TRPA1) as a potential
target to treat the pain of FD patients. Using the TRPA1 antagonist HC-030031, the mechanical pain
behavior in Fabry rats was reversed with success [60].
Although CRISPR-Cas9 was, in these cases, used for disease model generation and not for
gene/cell therapy, this work in models provides important insight for precise gene targeting of GLA.
This background information can be used in future gene therapy and integration of a nonmutated
GLA gene. Additionally, a good example of off-targeting occurrence, even in the presence of a highly
promising off-targeting score, has been reported. Off-targeting is more than a prevision, it is always a
real possibility.
In addition to disease modelling, gene editing for restoration of enzyme activity has also been done
using CRISPR-Cas9. In 2017, Sheng-Kai Chang and collaborators restored GLA enzyme activity in FD
patients’ fibroblasts after deleting the GLA IVS4 + 919 G > A mutation using CRISPR-Cas9. This specific
mutation seems to be related to the presentation of cardiac FD issues, with greater rate of incidence
in the Taiwanese population. The mutation interferes with the normal RNA splicing, producing a
truncated GLA protein with no enzyme activity. The therapy was performed with CRISPR-Cas9,
using two sgRNAs for the mutation deletion in FD patient fibroblasts, and demonstrated the proof
of principle as an increase in GLA activity and clearance of intracellular Gb3 was observed. This
work showed clear evidence that CRISPR-Cas9 has the potential for gene therapy directed to genetic
diseases [61].
3.3. Tay–Sachs and Sandhoff Diseases
Both diseases are caused by mutations of HEXA or/and HEXB genes. Michael Tropak et al.
achieved the disruption of HEXA and HEXB genes with CRISPR-Cas9 in HEK 293 cell line. Ultimately,
they aimed to modulate the disease with the intent of testing a lab-made chimeric enzyme with a single
hybrid µ-subunit. This subunit had a α-subunit active site, a stable β-subunit interface, and unique
areas in each subunit for GM2AP (GM2 activator protein) interaction [62].
Allende and collaborators successfully performed gene correction using CRISPR-Cas9 to treat
SD in patients’ cells. Fibroblasts of infantile SD patients were reprogramed to generate iPS cells that
would be used for modelling the disease. The reprograming of diseased fibroblasts was first carried
out via transfection of episomal vectors encoding the four reprogramming factors, OCT-3/4, SOX2,
KLF4, and L-MYC. The resulting iPSCs had normal karyotype, pluripotent markers, and were able
to form embryoid bodies that differentiated into the three embryonic germ layers. SD iPSCs showed
reduced β-hexosaminidase activity compared with control iPSCs, which were purchased. Once the SD
iPSCs model was prepared and tested, gene correction was performed. In order to correct the intron
10 acceptor splice-site mutation of HEXA gene, a plasmid was designed to express the sgRNA and
the Cas9 nuclease for DSB catalysis and selection with puromycin. For correction, a single-stranded
oligodeoxynucleotide of 181 bp was used as donor template. The template had a G to A correction, a
silent point mutation to disrupt the PAM sequence for no Cas9 recutting, and two silent point mutations
to create a KpnI restriction enzyme site for screening. Edited and not edited SD IPSCs were used for
cerebral organoid formation that would mimic the first trimester of neurodevelopment. The result
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was accumulation of GM2 ganglioside, higher cellular size, and proliferation only in the unedited
iPSCs [63].
Recent work using Prime editing, a new technique based on CRISPR-Cas9, has allowed for the
correction of the most common frequent causal mutation in the Ashkenazi Jewish population. The
mutation is a 4 bp insertion in HEXA (HEXA 1278 + TATC). PE3 prime editing was used to recreate
the mutation by installation of the 4 bp insertion into HEXA gene of lipoinfected HEK 293T cell
lines, resulting in 31% efficiency and 0.8% indels. Two isolated edited cells homozygous for HEXA
1278 + TATC mutation were then used to test 43 pegRNAs and three nicking sgRNAs with PE3 or
PE3b systems for correction of the pathogenic insertion. Nineteen of the pegRNAs resulted in ≥20%
successful editing reaching the best pegRNA, 33% efficiency, and 0.32% indels using PE3b [52].
3.4. Niemann–Pick Disease
In any disease, a cellular model is necessary to carry out gene and drug therapy tests. Although
NPD type C1 is not exactly a sphingolipidosis, but rather a lipid transport disease, CRISPR-Cas9
applications in this pathology are worth mentioning. Many developments have been made in disease
modelling. Descriptions of these developments are present in multiple types of sources, including
articles and protocol books. One example is “Cholesterol Homeostasis: Methods and Protocols,
Methods in Molecular Biology”, which describes with precision the generation of cellular NPC
cholesterol storage phenotypes in HeLa cells using CRISPR-Cas9 to disrupt the NPC1 gene [64].
Additionally, in vivo models, such as zebrafish NPC1-null mutants, have been generated using
CRISPR-Cas9 gene targeting. Two models were made, one for early liver NPC1 disease and one for
later neurological phenotype. sgRNAs, targeting exon 2 and 7, respectively, were injected with Cas9
mRNA into wild-type zebrafish embryos at the first cell stage. For mutation screening, the fish were
raised to adulthood and outcrossed with wild-type adults for later PCR and fragment analysis [65]. A
similar work has been also performed by Yusheng Lin et al. [66].
3.5. Krabbe Disease
In 2019, a work was published showing that GALC-expressing human neural stem cells (hNSCs)
can be engineered to secrete lysosomal enzymes that are able to cross-correct Krabbe fibroblasts in vitro.
To increase precision, multiple loci were targeted using Cas9 mRNA with modified synthetic gRNAs,
along with DNA donor templates. The transplantation of the altered hNSCs into oligodendrocyte
mutant shiverer-immunodeficient mice demonstrated migration and differentiation into astrocytes,
neurons, and myelin-producing oligodendrocytes. They also generated altered hNSCs with GALC
overexpression, capable of cross-correcting Galc enzyme activity via the mannose-6-phosphate receptor
pathway. Since the GALC gene is overexpressed, it would be of great interest to use such cells in cell
therapy for KD [67].
KD animal models have also been generated. For example, a gene knockdown of
galactocerebrosidase in zebrafish was obtained in two GALC co-orthologs (Galca and Galcb) [68].
3.6. GM1-Gangliosidosis and Morquio Syndrome
Yvonne Latour et al. generated in 2019, a GM1-gangliosidosis model with purchased iPSCs, and
consequently tested AAV9 gene therapy. Using CRISPR-Cas9, the researchers targeted exons 2 and
6 with different sgRNAs. The all-in-one plasmid method was used for expression of the complex in
the cells after electroporation. The GLB1 knockout was confirmed by β-gal enzyme activity assays
and DNA sequencing. The knockout iPSCs were then used to generate cerebral organoids that
revealed progressive accumulation of GM1 ganglioside. Finally, AAVrh9 (AAV9) vectors carrying
the human β-gal gene (AAV9-GLB1) or GFP (AAV9-GFP) were injected in GLB1 knockout organoids.
The result was an increase in β-gal activity and concomitant reduction in GM1 ganglioside content in
the AAV9-GLB1-injected organoids when compared with AAV9-GFP-injected organoids. This work
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contributed to the completion of the preclinical studies and progression to clinical trials using the
AAV9-GLB1 vector as capable of reversing the phenotype [69].
Another recent work was able to generate GM1-gangliosidose and Morquio syndrome type B
in mice models. Using CRISPR-Cas9, mutation W273L (position 274 in mice) was introduced into
the GLB1 gene to generate a Morquio B model, while for GM1-gangliosidosis, a 20bp mutation was
generated to remove the catalytic nucleophile of β-gal (β-gal-/-). The mice were generated by embryo
microinjection of Cas9 protein, sgRNA targeting exon 8, and in the case of Morquio syndrome type B
mice, a donor oligonucleotide to introduce a 2 bp mutation.
The generated Morquio syndrome type B mice showed reduction in β-gal enzyme activity,
but no marked phenotype after one year. β-gal-/- mice lost β-gal enzyme activity, resulting in
ganglioside accumulation and severe cellular vacuolation in the central nervous system (CNS), leading
to neuromotor and neurocognitive dysfunction with disease progression. This was the first model of
β-galactosidase deficiency with residual enzyme activity [70].
4. Conclusions
Since CRISPR-Cas9 was discovered, many advances have been made in gene editing for disease
treatment that were previously impossible. The main targets of research are the most common and
severe pathologies, such as cancer [71], which partly explains why there are still few gene therapies
based in CRISPR-Cas9 for the rare sphingolipidoses [72,73].
CRISPR-Cas9 has been widely applied to generate knockouts for the study of the mechanisms
underlying several diseases. The models created using CRISPR-Cas9 have already provided important
insights. Additionally, this tool is being used to test the involvement of infection agents in
the pathophysiology of diseases and the causality of novel genetic variants discovered through
next-generation sequencing (Table 1 summarizes several applications of CRISPR-Cas9).
Commonly used therapies in sphingolipidoses have limitations, such as not being able to cross the
blood–brain barrier or missing the target molecules. Some of these limitations can be circumvented by
CRISPR-Cas9 genome editing. This tool has the potential to alter, with a high degree of precision, very
specific sites of the genome. However, the off-target effects that arise from CRISPR-Cas9 editing cannot
be disregarded as they can have deleterious effects. As with other techniques, multiple checkpoints are
required at the gene and protein levels for the careful assessment of the results.
Undoubtedly, progress in the field of gene editing is rapid and further studies, not subjects of the
present work, demonstrated that other approaches to gene therapy, such as RNA [74] or viral-based
therapeutic approaches [75], provide useful insights for future applications. Prime editing already
provides an improved tool for genome editing, based on Cas9, with the advantage of being less prone
to off-targeting [52].
CRISPR-Cas9 has great potential for successful disease modelling, as well as for therapeutic
approaches, avoiding problems inherent to other treatments. In light of the versatility of this technique,
it is possible to envisage the development of other applications that have yet to be explored.
Funding: Fundação para a Ciência e a Tecnologia (Portugal, FCT) project PTDC/BIM-MEC/4762/2014.
Acknowledgments: We acknowledge the collaboration of Meg Quint in the proofreading of the manuscript and
the team at the Unit of R&D of DGH at INSA-Porto for the agreeable environment provided.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Cox, T.M.; Cachon-Gonzalez, M.B. The cellular pathology of lysosomal diseases. J. Pathol. 2012, 226, 241–254.
[CrossRef]
2. Platt, F.M.; D’Azzo, A.; Davidson, B.L.; Neufeld, E.F.; Tifft, C.J. Lysosomal storage diseases. Nat. Rev.
Dis. Primers 2018, 4, 27. [CrossRef]
3. Sandhoff, K. Sphingolipidoses. J. Clin. Pathol. Suppl. 1974, 8, 94–105. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 5897 13 of 16
4. Platt, F.M. Sphingolipid lysosomal storage disorders. Nature 2014, 510, 68–75. [CrossRef] [PubMed]
5. Arenz, C. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. 2017, 9, 1685–1698.
[CrossRef] [PubMed]
6. Do, J.; McKinney, C.; Sharma, P.; Sidransky, E. Glucocerebrosidase and its relevance to Parkinson disease.
Mol. Neurodegener. 2019, 14, 36. [CrossRef] [PubMed]
7. Ysselstein, D.; Shulman, J.M.; Krainc, D. Emerging links between pediatric lysosomal storage diseases and
adult parkinsonism. Mov Disord. 2019, 34, 614–624. [CrossRef] [PubMed]
8. Melum, E.; Jiang, X.; Baker, K.D.; Macedo, M.F.; Fritsch, J.; Dowds, C.M.; Wang, J.; Pharo, A.; Kaser, A.; Tan, C.;
et al. Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin. Nat. Immunol.
2019, 20, 1644–1655. [CrossRef]
9. Sardiello, M.; Palmieri, M.; di Ronza, A.; Medina, D.L.; Valenza, M.; Gennarino, V.A.; Di Malta, C.; Donaudy, F.;
Embrione, V.; Polishchuk, R.S.; et al. A gene network regulating lysosomal biogenesis and function. Science
2009, 325, 473–477. [CrossRef]
10. Palmieri Impey, S.; Kang, H.; di Ronza, A.; Pelz, C.; Sardiello, M.; Ballabio, A. Characterization of the CLEAR
network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 2011, 20, 3852–3866.
[CrossRef]
11. Farfel-Becker, T.; Do, J.; Tayebi, N.; Sidransky, E. Can GBA1-Associated Parkinson Disease Be Modeled in the
Mouse? Trends Neurosci. 2019, 42, 631–643. [CrossRef] [PubMed]
12. Horowitz, M.; Elstein, D.; Zimran, A.; Goker-Alpan, O. New Directions in Gaucher Disease. Hum. Mutat.
2016, 37, 1121–1136. [CrossRef] [PubMed]
13. Bennett, L.L.; Mohan, D. Gaucher Disease and Its Treatment Options. Ann. Pharmacother. 2013, 47, 1182–1193.
[CrossRef] [PubMed]
14. Zimran, A.; Belmatoug, N.; Bembi, B.; Deegan, P.; Elstein, D.; Fernandez-Sasso, D.; Giraldo, P.; Goker-Alpan, O.;
Lau, H.; Lukina, E.; et al. GOS Study group.Demographics and patient characteristics of 1209 patients with
Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS). Am. J. Hematol. 2018, 93,
205–212. [CrossRef]
15. Bendikov-Bar, I.; Horowitz, M.; Bendikov-Bar, I. Gaucher disease paradigm: From ERAD to comorbidity.
Hum. Mutat. 2012, 33, 1398–1407. [CrossRef]
16. Maor, G.; Rapaport, D.; Horowitz, M. The effect of mutant GBA1 on accumulation and aggregation of
α-synuclein. Hum. Mol. Genet. 2019, 28, 1768–1781. [CrossRef]
17. Migdalska-Richards, A.; Wegrzynowicz, M.; Rusconi, R.; Deangeli, G.; Di Monte, D.A.; Spillantini, M.G.;
Schapira, A.H.V. The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic
neurons in mice. Brain 2017, 140, 2706–2721. [CrossRef]
18. Duro, G.; Zizzo, C.; Cammarata, G.; Burlina, A.; Burlina, A.; Polo, G.; Scalia, S.; Oliveri, R.; Sciarrino, S.;
Francofonte, D.; et al. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? Int. J.
Mol. Sci. 2018, 19, 3726. [CrossRef]
19. Germain, D.P.; Elliott, P.M.; Falissard, B.; Fomin, V.V.; Hilz, M.J.; Jovanovic, A.; Kantola, I.; Linhart, A.;
Mignani, R.; Namdar, M.; et al. The effect of enzyme replacement therapy on clinical outcomes in male
patients with Fabry disease: A systematic literature review by a European panel of experts. Mol. Genet.
Metab. Rep. 2019, 19, 100454. [CrossRef]
20. Mehta, A.; Widmer, U. Chapter 19 Natural history of Fabry disease. In Fabry Dis Ease: Perspectives from 5
Years of FOS; Mehta, A., Beck, M., Sunder-Plassmann, G., Eds.; Oxford PharmaGenesis: Oxford, UK, 2006.
21. Waldek, S.; Feriozzi, S. Fabry nephropathy: A review—How can we optimize the management of Fabry
nephropathy? BMC Nephrol. 2014, 15, 72. [CrossRef]
22. Vu, M.; Li, R.; Baskfield, A.; Lu, B.; Farkhondeh, A.; Gorshkov, K.; Motabar, O.; Beers, J.; Chen, G.; Zou, J.; et al.
Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. Orphanet J.
Rare Dis. 2018, 13, 152. [CrossRef] [PubMed]
23. Hall, P.; Minnich, S.; Teigen, C.; Raymond, K. Diagnosing Lysosomal Storage Disorders: The GM2
Gangliosidoses. Curr. Protoc. Hum. Genet. 2014, 83, 16.1–16.8. [PubMed]
24. Karimzadeh, P.; Jafari, N.; Biglari, H.N.; Dari, S.J.; Abadi, F.A.; Alaee, M.-R.; Nemati, H.; Saket, S.;
Tonekaboni, S.H.; Taghdiri, M.-M.; et al. GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis
and Neuroimaging Findings (An Iranian Pediatric Case Series). Iran. J. Child Neurol. 2014, 8, 55–60. [PubMed]
Int. J. Mol. Sci. 2019, 20, 5897 14 of 16
25. Solovyeva, V.V.; Shaimardanova, A.A.; Chulpanova, D.S.; Kitaeva, K.V.; Chakrabarti, L.; Rizvanov, A.A. New
Approaches to Tay-Sachs Disease Therapy. Front. Physiol. 2018, 9, 1663. [CrossRef]
26. Duarte, A.J.; Ribeiro, D.; Oliveira, P.; Amaral, O. Mutation Frequency of Three Neurodegenerative Lysosomal
Storage Diseases: From Screening to Treatment? Arch. Med. Res. 2017, 48, 263–269. [CrossRef]
27. Kaback, M.M.; Desnick, R.J. Hexosaminidase A Deficiency. In GeneReviews; Adam, M.P., Ardinger, H.H.,
Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; University of Washington: Seattle,
WA, USA, 1993.
28. Vanier, M.T. Niemann-Pick diseases. Handb. Clin. Neurol. 2013, 113, 1717–1721.
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